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(Department of Medicine, Postgraduate Medical School ofLondon) METABOLIC bone disease is characteristically generalized as distinct from localized or invasive bone disease. But invasive bone disease, for example myeloma, may become widespread and so simulate a generalized or metabolic disease of bone; and on the other hand osteoporosis, a metabolic disease of bone, may predominantly affect the axial skeleton.
Much of the metabolic disorder of bone can be revealed from the metabolism of calcium and phosphorus; but in the future the metabolism of bone matrix may also provide diagnostic tools. Bone is constantly being deposited, remodelled and resorbed. Body fluids often reflect abnormalities of these processes; more direct measures of the rates of bone deposition give more sensitive reflections of bone metabolism.
The important metabolic bone disorders are those which cause thinning of bone and it is with the diagnosis of these disorders which we shall be concerned: (i) That due to excessive bone resorption, which is typically reflected in hypercalcemia with hypercalciuria and high serum alkaline phosphatase; low serum phosphate may reflect that hyperparathyroidism is the cause. (ii) That due to defective calcification or rickets or osteomalacia, which is typically reflected in the "low calcifiability serum", i.e. one showing a low calcium x phosphate product along with the probably compensatory high serum alkaline phosphatase. (iii) Insufficient bone formation or osteoporosis,, or bone atrophy with which we find normal serum levels of Ca and P and phosphatase.
(i) THE RECOGNITION OF EXCESSIVE BoNE RESORPTION DUE TO HYPERPARATHYROIDISM Gley recognized in 1890 that parathyroidectomy leads to tetany, and in 1909 McCallum and Voegtlin showed its association with low serum calcium and its relief by injected calcium. Following this, Erdheim in Vienna was led to study the parathyroids in cases of bone disease -and so to his discovery of the enlarged parathyroids in osteomalacia, which he correctly regarded as secondary. Later, however, thin bones with osteitis fibrosa were also found in his department to be associated with single parathyroid tumours which were clearly not of secondary origin. And so in 1926 a famous Viennese tram conductor, Albert, who had suffered many pathological fractures, was finally operated upon by Mandel and the offending parathyroid tumour was removed.
This pathological approach to hyperparathyroidism has its present-day counterpart in the recognition of hyperparathyroidism either by X-ray or by bone biopsy, i.e..in its recognition from signs of excessive bone resorption. But unfortunately, the typical pathology is only found in the severer instances of this bone disease. In these cases the excessive bone resorption can usually be recognized from X-rays of hands, where it is shown as subperiosteal erosion. This finding is also seen in uremic osteodystrophy (secondary hyperparathyroidism) and so is not a hallmark of primary hyperparathyroidism. For this distinction we must Proceedings of the Royal Society of Medicine 2 turn to the biochemical approach; as also for the recognition of those cases with less gross bone disease. Concurrently with these new Viennese pathological approaches to hyperparathyroidism, studies were being made on the calcium metabolism of similar cases in the U.S.A. In 1930, from a blood sample showing hypercalcemia, Dubois diagnosed hyperparathyroidism in another famous patient with pathological fractures, Captain Martell. Since then, the physicians Aub, Bauer and Albright and others, have studied many patients and defined the biochemical criteria for the diagnosis of hyperparathyroidism, based on the estimation of calcium and phosphorus and phosphatase in serum and urine. These procedures disclose parathyroid tumours not only among patients with bone disease, but even more among patients with renal stones and no bone disease.
In hyperparathyroidism with bone disease but without urwemia, these biochemical findings are typical-the raised serum and urinary calcium, associated with a raised serum alkaline phosphatase and a low serum P. However, only sera with at least two of these abnormalities are diagnostic, i.e. the associated phosphate disorders give the clue. But some cases of hyperparathyroidism do not have bone disease and so have a normal phosphatase, and some others have complicating urwemia so that their serum P is no longer low; fortunately either one or other of these phosphate abnormalities is present in the vast majority. Further, it has emerged over the last decade that several conditions may simulate these biochemical findings of hyperparathyroidism-but not both the Ca and P abnormalities. (a) A similar hypercalcaemia may occur in bone invasive disease such as myeloma or secondary carcinomatous involvement of bone; and also in some cases of sarcoidosis and in vitamin D poisoning. (b) With chronic uremia, secondary bone disease compounded of various abnormalities (uremic osteodystrophy) may occur; usually the absence of hypercalcLemia or hypercalciuria can exclude primary hyperparathyroidism or indeed any cause other than the uremia. Evidence for these conditions should always be sought in atypical cases. In secondary hyperparathyroidism the serum biochemistry will also reveal signs of the basic cause, i.e. of the uremia or of the osteomalacia. An assay of serum or urinary parathormone levels will obviously be a useful diagnostic tool in these atypical cases. At Hammersmith, Davies (1957) has shown that this is possible, on forty-eight-hour urine collections, using a benzoic acid extraction and a mouse-phosphaturia assay procedure.
We have noted that the diagnosis of primary parathyroid overaction is usually clinched by finding abnormal P metabolism in association with hypercalcemia. It is sometimes useful to exclude the suspicion of hyperparathyroidism by assessing both the serum level and the renal excretion of P. Primary and secondary hyperparathyroidism and also several other conditions, including renal disease and Cushing's syndrome are characterized by a high urinary P excretion. The urinary P excretion can only be assessed in the light of both the serum P level and of the renal glomerular filtration rate. If we estimate the ratio of the renal clearance of P to that of creatinine then we can derive a "phosphate excretion index" (Nordin and Fraser, 1956a) , which will be high in hyperparathyroidism primary or secondary, as well as in the other conditions noted, and low in hypoparathyroidism. This procedure is useful for the recognition of hypoparathyroidism and for the exclusion of hyperparathyroidismbut when high the index does not help distinguish hyperparathyroidism from the conditions which can simulate it.
(ii) THE RECOGNITION OF OSTEOMALACIA OR RICKETS A firm diagnosis requires the demonstration both of the cause of the osteomalacia and also that the serum has a lowered calcifying power. I shall not discuss the ascertainment of the cause, i.e. the assessment of absorption and also of renal tubular function. In the welldeveloped cases, the radiological findings alone may be diagnostic-revealing the softness of the bones either by deformities or by Milkman's or partial greenstick-like fractures. In the young there will also be seen the widened translucent metaphysis which is hyperplastic but inadequately calcified.
In the typical case, the biochemical criteria of low calcifiability are found in the seruma low product of the Ca x P concentrations-together with a high phosphatase level indicative of the hyperplastic osteoid. It is usually the P level which is low, but because of the considerable diurnal and dietary variations in serum P levels this abnormality may not always be recognizable from serum levels alone. For the recognition of doubtful or atypical cases, and for the assessment of cass with a known cause such as steatorrhaea but with no clear evidence of bone involvement, we have two further tests available-the calcium infusion test and the bone biopsy. The osteomalacic bones show an abnormal avidity for intravenous infused Ca. If we exclude the vitamin D-resistant cases, which show a urinary leak for Ca, this can be shown by the low 0-12-hour urinary excretion on the test (Nordin and Fraser, 1956b) . This test can recognize cases before the serum levels are obviously abnormal. If account is also taken of the rise in serum levels during the infusion, we can also calculate a four-hour bone retention: which is abnormally high in osteomalacia, including the vitamin D-resistant cases.
Further confirmation can be obtained by iliac crest biopsy. For this procedure it is necessary to prepare undecalcified bone sections so that the abnormally wide osteoid seams may be demonstrated. A final confirmation of the diagnosis of osteomalacia is best obtained by the demonstration of the response to treatment appropriate to the cause discoverede.g. injected vitamin D in cases of steatorrhoea. If need be in doubtful cases, this may be confirmed by showing the increased retention of calcium by balance studies.
(iii) THE RECOGNITION OF OSTEOPOROSIS Finally we come to cases with translucent bones without evidence of a primary disorder of Ca metabolism, or of a bone invasive disease. For these cases we reserve the term osteoporosis and the diagnosis at present rests mainly on the exclusion of other disease. It is commonly attributed to defective formation of bone matrix, since what forms is normally calcified; but this basis has not yet been proved or disproved. The radiological diagnosis here consists in the recognition that the bones are abnormally thin. Unfortunately, so much of the "bone density" on an X-ray depends on the soft tissues shadow that variations in body thickness are a large source of error here; and at least about 25 % of the body's Ca has to be lost before a recognizable abnormality emerges. There are two tests which may help in the recognition of a metabolic defect in these cases of osteoporosis; the Ca infusion test and the strontium infusion test.
The first test has already been mentioned as useful in the recognition of osteomalacia. The four-hour "bone retention" of Ca on this test tends to be-low in osteoporosis (Finlay, Nordin and Fraser, 1956 ). This first test might be called the early Ca uptake in response to a raised serum Ca level.
In order to observe the bone uptake without raising the serum Ca, we should have to inject a suitable tracer of the Ca atoms and observe their rate of disappearance from the body fluids. For this purpose we have used strontium rather than the possibly dangerous radioactive isotopes and found evidence that it does act as a tracer for Ca in the body. We have given a single intravenous dose of strontium and followed the changing concentrations of strontium in the serum and urine over the subsequent seven days. From this data we have been able to derive the daily uptake of Ca by the bones (Eisenberg, Fraser, Ibbertson and Lowe, 1957) .
Interpretation of the curve suggests that there are two main Ca pools in the body. The body-Ca pool, or the exchangeable Ca, comprising not only the Ca in the body fluids but also that on the surface of the bones which appears to exchange freely with the body fluids; and the deeper or deposited bone Ca to which there is a steady deposition and from which there is later a steady resorption. This test measures the size of the first or exchangeable Ca poolfrom the extent to which the strontium becomes diluted at the conclusion of mixing. We cannot follow the curves long enough to observe the end of the cycle-the resorption of deposited bone; but the steady rate of strontium disappearance, when corrected for urinary loss, reflects the rate of bone deposition from the exchangeable pool. Abnormal resorption should be revealed on this test by a corresponding abnormality in bone deposition and any imbalance between these processes should be revealed from the Ca balance. Preliminary results show that this dynamic test can more precisely define the disordered Ca metabolism of some bone disorders, than can either estimation of the levels of Ca in the serum and urine or balance studies. Severe thyrotoxicosis shows a depleted Ca pool and a rapid bone turnover; some cases of severe simple osteoporosis show a normal Ca pool but defective bone deposition. Hyperparathyroidism shows both an enlarged exchangeable Ca pool and increased rate of bone turnover.
In conclusion, we see that in severe cases, radiology alone can sometimes define the disorder, and standard biochemical procedures can clinch the diagnosis in these cases. For the diagnosis of hyperparathyroidism or osteomalacia, the estimation of serum and urinary levels of Ca, P and phosphatase can often supply the diagnosis. But hyperparathyroidism without bone disease or with uremia, may be mimicked by certain other diseases. Infusion tests of Ca and strontium can reveal abnormalities in cases of early osteomalacia and of osteoporosis, though the serum biochemistry may appear normal; these dynamic tests may help to elucidate obscure cases.
